The American Academy of Neurology (AAN) has updated its guidelines on the use of botulinum neurotoxins in neurological disorders. The new guidelines provide individual recommendations for the four products that are commercially available in the USA; however, the clinical differences between the products are still not clear.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Simpson, D. M. et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache : report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86, 1818–1826 (2016).
Simpson, D. M. et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70, 1691–1698 (2008).
Simpson, D. M. et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70, 1699–1706 (2008).
Naumann, M. et al. Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70, 1707–1714 (2008).
Albanese, A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA 305, 89–90 (2011).
Albanese, A. et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur. J. Neurol. 18, 5–18 (2011).
Perry, W. B., Dykes, S. L., Buie, W. D. & Rafferty, J. F. Practice parameters for the management of anal fissures (3rd revision). Dis. Colon Rectum 53, 1110–1115 (2010).
Govindarajan, R., Shepard, K. M., Moschonas, C. & Chen, J. J. Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Payment policy perspectives. Neurol. Clin. Pract. 6, 1–6 (2016).
Albanese, A. et al. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J. Neurol. 262, 2201–2213 (2015).
Marion, M. H., Humberstone, M., Grunewald, R. & Wimalaratna, S. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin. Pract. Neurol. http://dx.doi.org/10.1136/practneurol-2015-001335 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received speaker's honoraria from Allergan, Ipsen and Merz.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Albanese, A. No more mistaken identities for botulinum neurotoxins. Nat Rev Neurol 12, 373–374 (2016). https://doi.org/10.1038/nrneurol.2016.86
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2016.86
